REPRIEVE.png

REPRIEVE EU - Randomized Trial to Prevent Vascular Events in HIV

A phase III study evaluating the effect of Pitavastatin to prevent cardiovascular events in HIV-1 infected individuals

NEAT ID EU5332

EUDRACTNumber: 2018-001285-41

CO-SPONSORS:

NEAT ID Foundation & Massachusetts  General Hospital 

Indication: HIV-infected patients on ART considered at low to moderate risk for cardiovascular disease and without a history of cardiovascular disease

 

Countries: Spain

Sites: 13

Status: Closed to Recruitment